Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 68071-3653

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 68071-3653). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3653 9)

NuCare Pharmaceuticals Venlafaxine Hydrochloride 75 mg extended-release capsules label for a #90 capsule bottle. The label includes NDC 68071-3653-9 and states the product is manufactured by Yichang Humanwell Oral Solid Plant in China. It includes directions to see the manufacturer's label for full ingredients and a warning to keep out of reach of children. Additional details include storage temperature instructions and barcode information.*

FDA Label Image

Image-01 (Image 01)

Chemical structure of venlafaxine hydrochloride, showing its molecular composition and arrangement including a cyclohexane ring, methoxy-substituted aromatic ring, and a dimethylaminoethyl side chain with hydroxyl group.*

FDA Label Image

Image-02 (Image 02)

Pharmacokinetic chart presenting fold changes with 90% confidence intervals for venlafaxine and its ODV metabolite in various special populations and conditions. The chart lists analyte types (venlafaxine, ODV), pharmacokinetic parameters (Cmax, AUC), and special populations including hepatic impairment stages, renal impairment stages, CYP2D6 polymorphism, age above 60 years, and gender differences. It shows changes relative to a reference value on the x-axis.*

FDA Label Image

Image-03 (Image 03)

A scatter plot chart showing fold changes with 90% confidence intervals for pharmacokinetic parameters (Cmax and AUC) of venlafaxine and its metabolite ODV when co-administered with various interacting drugs. The X-axis represents change relative to reference value, and the Y-axis lists interacting drugs including ethanol, diazepam, cimetidine, ketoconazole, indinavir, metoprolol, imipramine, and lithium.*

FDA Label Image

Image-04 (Image 04)

A forest plot showing fold change and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC of various analytes interacting with different drugs. The x-axis represents change relative to the reference value, with points indicating fold change and error bars for confidence intervals for drugs such as ethanol, diazepam, alprazolam, indinavir, metoprolol, risperidone, imipramine, haloperidol, caffeine, tolbutamide, and lithium.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.